MicroRNA‐181a promotes docetaxel resistance in prostate cancer cells
CM Armstrong, C Liu, W Lou, AP Lombard… - The …, 2017 - Wiley Online Library
BACKGROUND Docetaxel is one of the primary drugs used for treating castration resistant
prostate cancer (CRPC). Unfortunately, over time patients invariably develop resistance to …
prostate cancer (CRPC). Unfortunately, over time patients invariably develop resistance to …
MicroRNA‐181a promotes docetaxel resistance in prostate cancer cells
CM Armstrong, C Liu, W Lou, AP Lombard, CP Evans… - The Prostate, 2017 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> BACKGROUND</jats: title>< jats: p> Docetaxel is one of the
primary drugs used for treating castration resistant prostate cancer (CRPC). Unfortunately …
primary drugs used for treating castration resistant prostate cancer (CRPC). Unfortunately …
MicroRNA‐181a promotes docetaxel resistance in prostate cancer cells
CM Armstrong, C Liu, W Lou, AP Lombard… - The …, 2017 - escholarship.org
BackgroundDocetaxel is one of the primary drugs used for treating castration resistant
prostate cancer (CRPC). Unfortunately, over time patients invariably develop resistance to …
prostate cancer (CRPC). Unfortunately, over time patients invariably develop resistance to …
[HTML][HTML] MicroRNA-181a promotes docetaxel resistance in prostate cancer cells
CM Armstrong, C Liu, W Lou, AP Lombard… - The Prostate, 2017 - ncbi.nlm.nih.gov
Background Docetaxel is one of the primary drugs used for treating castration resistant
prostate cancer (CRPC). Unfortunately, over time patients invariably develop resistance to …
prostate cancer (CRPC). Unfortunately, over time patients invariably develop resistance to …
MicroRNA‐181a promotes docetaxel resistance in prostate cancer cells
CM Armstrong, C Liu, W Lou, AP Lombard, CP Evans… - The Prostate, 2017 - infona.pl
BACKGROUND Docetaxel is one of the primary drugs used for treating castration resistant
prostate cancer (CRPC). Unfortunately, over time patients invariably develop resistance to …
prostate cancer (CRPC). Unfortunately, over time patients invariably develop resistance to …
[PDF][PDF] MicroRNA-181a promotes docetaxel resistance in prostate cancer cells
CM Armstrong, C Liu, W Lou, AP Lombard, CP Evans… - Prostate, 2017 - researchgate.net
Background—Docetaxel is one of the primary drugs used for treating castration resistant
prostate cancer (CRPC). Unfortunately, over time patients invariably develop resistance to …
prostate cancer (CRPC). Unfortunately, over time patients invariably develop resistance to …
MicroRNA-181a promotes docetaxel resistance in prostate cancer cells
CM Armstrong, C Liu, W Lou, AP Lombard… - The …, 2017 - pubmed.ncbi.nlm.nih.gov
Background Docetaxel is one of the primary drugs used for treating castration resistant
prostate cancer (CRPC). Unfortunately, over time patients invariably develop resistance to …
prostate cancer (CRPC). Unfortunately, over time patients invariably develop resistance to …
MicroRNA-181a promotes docetaxel resistance in prostate cancer cells.
CM Armstrong, C Liu, W Lou, AP Lombard, CP Evans… - The Prostate, 2017 - europepmc.org
Background Docetaxel is one of the primary drugs used for treating castration resistant
prostate cancer (CRPC). Unfortunately, over time patients invariably develop resistance to …
prostate cancer (CRPC). Unfortunately, over time patients invariably develop resistance to …
MicroRNA-181a promotes docetaxel resistance in prostate cancer cells.
CM Armstrong, C Liu, W Lou, AP Lombard, CP Evans… - The Prostate, 2017 - europepmc.org
Background Docetaxel is one of the primary drugs used for treating castration resistant
prostate cancer (CRPC). Unfortunately, over time patients invariably develop resistance to …
prostate cancer (CRPC). Unfortunately, over time patients invariably develop resistance to …